Divided Congress Doesn't Have to Mean Gridlock Over Healthcare
 
Newsmax | Sally Pipes
November 22, 2022

As a result of the recent midterm elections, and as of this writing, it looks like the 118th Congress, which will be seated Jan. 3, 2023 will be split, with Democrats set to retain a slim majority in the Senate and Republicans taking control of the House by just a narrow margin of seats.

But divided government doesn’t necessarily mean legislative gridlock.


Read more. . .

What is the Value of the Interchangeability Designation for a Biosimilar?
 
American Journal of Managed Care | Wayne Winegarden, Robert Popovian & Peter Pitts
November 13, 2022

Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we embark on the primary target: the launch of Humira (adalimumab) biosimilars. Humira is by far the all-time biopharmaceutical revenue generator, with more than $15 billion in US sales in 2021.^[1]


Read more. . .

A New Plan Brings Clarity To Healthcare Price Transparency - Finally
 
Forbes | Sally Pipes
November 21, 2022

In health policy, there’s nothing quite as opaque as price transparency. Insurance companies and hospitals tend to say there’s no place for it in the healthcare sector, since medicine is more complicated than cars or groceries.

Other skeptics say that implementing transparency rules is too hard. Hospitals have largely flouted a two-year-old Trump administration directive that they post their prices online. Parsing the pricing information of those that have complied appears to be beyond the skill set of most ordinary consumers.


Read more . . .